Table 2 Risks of hypertension with abiraterone
From: Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
MOA | Incidence (95% CI) | Relative risk (95% CI) | References | |
|---|---|---|---|---|
abiraterone and prednisone | Androgen biosynthesis (CYP-17 inhibitor) | 21.9% (13.6–33.2%) | 1.80 (1.47–2.19) | This study |
enzalutamide [26] | Anti-Androgen receptor | 14% | 3.41 | Package insert a |
leuprolide [34] | Androgen biosynthesis (LHRH analogs) | 6.6% | NA | Package insert |
firmagon [35] | Androgen biosynthesis (LHRH antagonist) | 7% | NA | Package insert |